Indaptus Therapeutics
INDP
16 hedge funds and large institutions have $750K invested in Indaptus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0.04% less ownership
Funds ownership: 0.25% → 0.21% (-0.04%)
16% less funds holding
Funds holding: 19 → 16 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
41% less capital invested
Capital invested by funds: $1.26M → $750K (-$512K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.23K |
| 3 |
Renaissance Technologies
New York
|
+$884 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$11.9K |
| 2 |
IHL
Investment House LLC
Redondo Beach,
California
|
-$4.27K |
| 3 |
BHWM
Beaird Harris Wealth Management
Dallas,
Texas
|
-$636 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$295 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$167 |
INDP Hedge Fund Activity: Q3 2024 in Review
16 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2024, worth a combined $750K — down 41% from $1.26M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of INDP and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $24.2K. The largest seller was Citadel Advisors, cutting an estimated $11.9K.
- 16 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2024, down from 19 in Q2 2024.
- Funds reported $750K of Indaptus Therapeutics stock for Q3 2024, down 41% quarter-over-quarter.
- 0 funds opened new Indaptus Therapeutics positions in Q3 2024 and 3 closed out, a net change of -3 holders.
- The largest Indaptus Therapeutics buyer in Q3 2024 was Geode Capital Management, an estimated $24.2K added.
- The largest Indaptus Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $11.9K sold.
Based on aggregated 13F filings for Q3 2024.